George Padron Oncology Care, Biomarker & Genomic Testing, GU Cancers | Jun 20, 2026 An updated Cochrane review of almost 800,000 men finds PSA screening likely reduces prostate cancer deaths, about one per 500 invited, set against overdiagnosis risk.
George Padron Oncology Care, GU Cancers | May 15, 2026 ARANOTE Black men subgroup: darolutamide plus ADT cut progression or death risk 49% versus ADT alone in metastatic hormone-sensitive prostate cancer.
Sonia Reyes Oncology Care, GU Cancers | May 15, 2026 ARASEC phase 2, presented at AUA 2026, showed darolutamide plus ADT reduced progression risk 71% versus matched ADT alone in 320 US patients with mCSPC
🔎︎
